News Headlines
-
Innovation In Generics: Increased Efficiency Through Peptide API Synthesis Expertise
5/2/2024
Leading Swiss pharmaceutical company Bachem explains the benefits of converging LPPS in the manufacturing of Gonadotropin-releasing hormone (GnRH) analogues
-
Astellas And Poseida Therapeutics Enter Into Research Collaboration And License Agreement To Develop Novel Allogeneic Cell Therapies In Oncology
5/1/2024
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Poseida Therapeutics, Inc. (NASDAQ: PSTX, President and CEO: Kristin Yarema, "Poseida") today announced that Xyphos Biosciences, Inc., (a wholly owned subsidiary of Astellas, "Xyphos") and Poseida have entered into a research collaboration and license agreement to develop novel convertibleCAR® programs by combining the innovative cell therapy platforms from each of the companies.
-
Adare Expands Global High Potency Handling & Packaging Capabilities
5/1/2024
Adare Pharma Solutions, a global technology-driven CDMO specializing in oral dosage forms, today announced expansions of its high potency handling capabilities in the United States and Europe.
-
AbbVie Reinforces Commitment To Science And Innovation With A €150M Euro Investment In New Cutting-Edge Research And Development Facility In Germany
4/30/2024
AbbVie breaks ground on a new central research building, “LUnA” (LUdwighafens neue Arbeitswelt) and is investing approximately €150M in its second largest R&D location worldwide.
-
Phosphorex And NOF CORPORATION Collaborate To Supply Lipid Nanoparticle Formulations Using NOF's Proprietary Ionizable Lipid, COATSOME® SS Series
4/30/2024
Phosphorex, an Ampersand Capital Partners company and drug delivery-focused contract development and manufacturing organization ("CDMO"), announced today a collaboration with NOF CORPORATION to supply its global clients with NOF's COATSOME® SS Series proprietary ionizable lipids, further enhancing its leading position in providing lipid nanoparticle (LNP)-based drug delivery solutions to the market.
-
Cytiva Introduces New Cell Lines To Meet The Challenges And Increasing Demand Of Viral Vector Manufacturing
4/30/2024
Viral vector-based gene therapies hold immense promise for treating a multitude of diseases. However, their widespread adoption has been hindered by inefficient manufacturing methods and the absence of established standardized processes, resulting in high costs and limited accessibility for patients. Global life sciences leader, Cytiva, is bringing solutions to these challenges with its new ELEVECTA cell lines.
-
TriLink BioTechnologies And Lonza Enter Into Non-Exclusive License And Supply Agreement For CleanCap mRNA Capping Technology
4/30/2024
TriLink BioTechnologies (TriLink), a Maravai LifeSciences company and global provider of life science reagents and services, has signed a non-exclusive License and Supply Agreement with Lonza, a global development and manufacturing partner to the pharma, biotech and nutrition industries.
-
INCOG BioPharma Services Continues Positive Momentum
4/30/2024
INCOG BioPharma Services proudly announces that its sterile injectable manufacturing facility has received approval from the U.S. Food and Drug Administration (FDA) to produce a commercially approved drug product.
-
Bespak And H&T Presspart Enter Into Collaboration Agreement To Advance Transition To Low GWP Propellants In pMDIs
4/29/2024
Bespak, a leading contract development and manufacturing organisation (CDMO) focussed on orally inhaled and nasal drug-device combination products, and H&T Presspart, a market leader in the development, manufacturing and supply of inhaled drug delivery components and devices, announced today a collaboration to accelerate the industry’s transition from existing pressurised Metered Dose Inhaler (pMDI) formulations to more climate-friendly alternatives utilising low global warming potential (GWP) propellants.
-
Lonza Launches AI-Enabled Route Scouting Service To Accelerate Small Molecule Development
4/29/2024
Lonza, a global partner to the pharmaceutical, biotech and nutraceutical markets, today announced the launch of its AI-enabled Route Scouting Service offering.